{"id":52349,"date":"2025-08-26T07:09:12","date_gmt":"2025-08-26T11:09:12","guid":{"rendered":"https:\/\/stockmarketwatch.com\/stock-market-news\/market-movers-eli-lillys-oral-glp-1-shines-att-secures-23-billion-spectrum-deal\/52349\/"},"modified":"2025-08-26T07:09:12","modified_gmt":"2025-08-26T11:09:12","slug":"market-movers-eli-lillys-oral-glp-1-shines-att-secures-23-billion-spectrum-deal","status":"publish","type":"post","link":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/market-movers-eli-lillys-oral-glp-1-shines-att-secures-23-billion-spectrum-deal\/52349\/","title":{"rendered":"Market Movers: Eli Lilly&#8217;s Oral GLP-1 Shines, AT&#038;T Secures $23 Billion Spectrum Deal"},"content":{"rendered":"<h2>Key Takeaways<\/h2>\n<ul>\n<li><strong>Eli Lilly&#39;s (<a href=\"\/stock\/LLY\">LLY<\/a>)<\/strong> investigational oral GLP-1 agonist, <strong>Orforglipron<\/strong>, has delivered positive results across multiple Phase 3 trials, showing significant weight loss and A1C reductions, completing the necessary clinical data for global regulatory submissions.<\/li>\n<li><strong>AT&amp;T (<a href=\"\/stock\/T\">T<\/a>)<\/strong> announced a substantial <strong>$23 billion<\/strong> all-cash acquisition of spectrum licenses from <strong>EchoStar (<a href=\"\/stock\/SATS\">SATS<\/a>)<\/strong>, reinforcing its 5G and home internet capabilities while reaffirming its <strong>2025 financial guidance<\/strong> and a <strong>$20 billion share repurchase plan<\/strong> for 2025-2027.<\/li>\n<li><strong>PetroChina (<a href=\"\/stock\/PTR\">PTR<\/a>)<\/strong> plans to acquire gas storage companies in a deal valued at <strong>40 billion Yuan<\/strong>, signaling strategic investments in energy infrastructure.<\/li>\n<li><strong>Bitwise<\/strong> has filed for a spot <strong>Chainlink ETF<\/strong>, reflecting the increasing institutional interest in cryptocurrency-backed exchange-traded funds.<\/li>\n<\/ul>\n<h3>Eli Lilly&#39;s Orforglipron Shows Strong Phase 3 Results<\/h3>\n<p>Eli Lilly and Company (<a href=\"\/stock\/LLY\">LLY<\/a>) has reported compelling positive topline results from its Phase 3 clinical trial program for <em>orforglipron<\/em>, an investigational once-daily oral glucagon-like peptide-1 (GLP-1) receptor agonist, for both obesity and type 2 diabetes. The drug met all primary and key secondary endpoints across multiple studies, positioning it for global regulatory submissions.<\/p>\n<p>In the <strong>ATTAIN-1 trial<\/strong>, evaluating adults with obesity or overweight without diabetes, the highest dose of orforglipron (36 mg) led to an average weight reduction of <strong>12.4% (27.3 lbs)<\/strong> over 72 weeks, compared to 0.9% (2.2 lbs) with placebo. Furthermore, 59.6% of participants on the highest dose achieved at least 10% weight loss, with 39.6% losing 15% or more. The trial also indicated reductions in cardiovascular risk markers such as non-HDL cholesterol, triglycerides, and systolic blood pressure.<\/p>\n<p>For patients with obesity or overweight and type 2 diabetes, the <strong>ATTAIN-2 trial<\/strong> demonstrated that orforglipron 36 mg reduced weight by an average of <strong>10.5% (22.9 lbs)<\/strong>, alongside a significant <strong>1.8% reduction in A1C<\/strong>. In the <strong>ACHIEVE-1 trial<\/strong> focusing on type 2 diabetes, orforglipron lowered A1C by an average of <strong>1.3% to 1.6%<\/strong> from a baseline of 8.0%, with over 65% of patients on the highest dose achieving an A1C of \u22646.5%. This trial also showed an average weight loss of <strong>7.9% (16.0 lbs)<\/strong> at the highest dose.<\/p>\n<p>Eli Lilly plans to submit <em>orforglipron<\/em> for regulatory review for obesity by the end of 2025, with a submission for type 2 diabetes anticipated in 2026. Despite the strong clinical data, Lilly&#39;s stock saw a <strong>14% drop<\/strong> following the ATTAIN-1 results, as some market expectations for weight loss were higher, comparing it to injectable competitors like Novo Nordisk&#39;s Wegovy and Lilly&#39;s own Zepbound, which have shown greater weight reduction percentages.<\/p>\n<h3>AT&amp;T&#39;s Strategic $23 Billion Spectrum Acquisition<\/h3>\n<p>Telecommunications giant AT&amp;T (<a href=\"\/stock\/T\">T<\/a>) has announced a significant agreement to acquire wireless spectrum licenses from EchoStar (<a href=\"\/stock\/SATS\">SATS<\/a>) for approximately <strong>$23 billion<\/strong> in an all-cash transaction. This deal includes roughly <strong>30 MHz of nationwide 3.45 GHz mid-band spectrum<\/strong> and <strong>20 MHz of 600 MHz low-band spectrum<\/strong>, totaling about <strong>50 MHz<\/strong> across over 400 markets in the U.S. The acquisition is expected to bolster AT&amp;T&#39;s 5G wireless and home internet (AT&amp;T Internet Air) capabilities, enabling rapid deployment of the newly acquired mid-band licenses.<\/p>\n<p>The transaction is anticipated to close in mid-2026, pending regulatory approvals. AT&amp;T intends to finance the purchase using existing cash reserves and incremental borrowings. The company has reaffirmed its <strong>full-year 2025 financial guidance<\/strong> and its plans for <strong>$20 billion in share repurchases<\/strong> between 2025 and 2027. While the net debt-to-adjusted EBITDA ratio is projected to temporarily increase to 3x, AT&amp;T aims to return to its long-term target of 2.5x within approximately three years.<\/p>\n<p>In a related development, AT&amp;T and EchoStar have enhanced their wholesale network services agreement, which will allow EchoStar to operate as a hybrid mobile network operator under the Boost Mobile brand, leveraging AT&amp;T&#39;s extensive network. This strategic partnership is also seen as a step by EchoStar to address inquiries from the Federal Communications Commission (FCC) regarding spectrum utilization. Citi (<a href=\"\/stock\/C\">C<\/a>) has assigned a positive 90-day short-term view to AT&amp;T, anticipating improved market confidence in the stock.<\/p>\n<h3>Other Market Highlights<\/h3>\n<p>In the energy sector, <strong>PetroChina (<a href=\"\/stock\/PTR\">PTR<\/a>)<\/strong> has announced plans for a significant investment, looking to acquire gas storage companies for <strong>40 billion Yuan<\/strong>. This move underscores the company&#39;s strategy to enhance its energy infrastructure and capabilities.<\/p>\n<p>The digital asset space continues to evolve with <strong>Bitwise<\/strong> filing for a spot <strong>Chainlink ETF<\/strong>. This development signals growing mainstream acceptance and investment product diversification within the cryptocurrency market.<\/p>\n<p>Globally, the European Union has addressed concerns regarding its digital regulations, stating that claims of censorship are &quot;unfounded.&quot; Meanwhile, an opinion piece highlighted the robust growth in global jet fuel demand, driven by the increasing air travel aspirations of wealthy Asian urbanites, suggesting a bright spot for oil demand.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Key Takeaways Eli Lilly&#39;s (LLY) investigational oral GLP-1 agonist, Orforglipron, has delivered positive results across multiple Phase 3 trials, showing [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":50383,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"rank_math_schema_Article":[],"rank_math_focus_keyword":[],"rank_math_description":[],"financial_data_references":[],"stock_symbols_mentioned":[],"footnotes":""},"categories":[5012],"tags":[5775,9444,337,6163,9445,1810,6289,9446,3774,6319,9447,3792,6761,9448,6801,5030,9433,5171,9440,5311,9441,5380,9442,5694,9443],"class_list":["post-52349","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-breaking-news","tag-pharmaceuticals","tag-spectrum","tag-lly","tag-diabetes","tag-5g","tag-sats","tag-share-repurchase","tag-chainlink","tag-c","tag-acquisitions","tag-financial-guidance","tag-t","tag-eli-lilly","tag-ptr","tag-glp-1","tag-energy","tag-petrochina","tag-telecommunications","tag-att","tag-digital-assets","tag-echostar","tag-etfs","tag-orforglipron","tag-fcc","tag-weight-loss"],"_links":{"self":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/52349","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/comments?post=52349"}],"version-history":[{"count":0,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/52349\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media\/50383"}],"wp:attachment":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media?parent=52349"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/categories?post=52349"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/tags?post=52349"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}